Posted in | Mass Spectrometry

Deciphering Acute Kidney Injury Mechanisms and Breast Cancer Subtypes with Fast Acquisition Mass Spectrometry

With recent improvements in acquisition speed and sensitivity of mass spectrometers, coupled with the robustness and throughput provided by microflow chromatography, researchers can now analyze large numbers of biological samples with short run times, accelerating biological research.

About this webinar: 

Birgit shares her research around Acute Kidney Injury (AKI) and human breast cancer in this webinar. 

She discusses how her lab at the Buck Institute for Research on Aging, utilized the latest high-resolution mass spectrometry solution from SCIEX, the ZenoTOF 7600 system, and a novel high-sensitivity data independent acquisition workflow, Zeno SWATH DIA, to study both a mouse acute kidney injury model (AKI) and a human breast cancer cohort that consisted of FFPE-preserved specimen of 5 cancer subtypes and healthy controls.

Benefits of ZenoTOF

By attending this webinar, you will learn:

  • Comprehensive data independent acquisition, with 80 variable windows, is a fast robust MS workflow for deciphering disease mechanisms and disease pathways
  • Short microflow gradients maintain quantification accuracy and accelerate quantitative protein profiling workflows in mammalian tissues 
  • The kidney proteome is completely remodeled during kidney injury
  • Optimized FFPE tissue analysis (with up to 6,000 proteins quantified) highlights breast cancer biology and cancer progression in 5 different breast cancer subtypes

About the speaker: 

Dr. Birgit Schilling has worked at the Buck Institute for Research on Aging in the San Francisco Bay Area since 2000 as Professor and Director of the Mass Spectrometry Technology Center, specifically focusing on data independent acquisition technologies and large-scale proteome quantification.

Dr. Schilling received her Ph.D. in Germany and then moved to the University of California San Francisco (UCSF) as a postdoctoral fellow.

Dr. Schilling is interested in translational research and research that may aim toward therapeutic interventions to improve human aging or age-related diseases, specifically osteoarthritis, kidney injury and cancer.

Dr. Schilling uses modern proteomic technologies to investigate mechanisms of aging, senescence and cancer and uses this knowledge to develop biomarkers and targets for interventions.

Who should attend this webinar: 

This webinar is aimed at people working as application scientists, postdoctoral fellows/researchers, professors/assistants/associate professors, lab supervisors/managers/directors, or staff scientists in any of these fields/institutions (but not limited to): Academic Research, Pharmaceuticals, Life Science Research, Proteomics Centers/Institutes, Cancer Research Centers, Disease Research Centers, Mass spectrometry Labs, Hospitals, CRO/CMOs, Drug Discovery Labs and more.

Life Science Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.